Afstyla Approval History
- FDA approved: Yes (First approved May 25th, 2016)
- Brand name: Afstyla
- Generic name: antihemophilic factor (recombinant), single chain
- Dosage form: for Injection
- Company: CSL Behring
- Treatment for: Hemophilia A
Afstyla (antihemophilic factor (recombinant), single chain, is a recombinant, antihemophilic factor indicated for the control and prevention of bleeding episodes in adults and children with hemophilia A.
FDA approval of Afstyla is based on results from the AFFINITY clinical development program which included safety and efficacy studies in adults, adolescents, and children with hemophilia A. Data showed that patients treated prophylactically had a median annualized spontaneous bleeding rate (AsBR) of 0.00, and median annualized bleeding rate (ABR) of 1.14 in adults and adolescents, and 3.69 in children. Data also showed that of 1,195 bleeds treated, 94 percent of adults and adolescents, and 96 percent of children were controlled with no more than two infusions of Afstyla weekly, with 81 percent of adult and adolescents, and 86 percent of children effectively controlled by just one infusion.
Afstyla is administered via intravenous injection. Patients should be aware that hypersensitivity reactions, including anaphylaxis, are possible and Afstyla should be discontinued immediately, and appropriate treatment administered if symptoms occur.
The most common side effects reported in clinical trials were dizziness and hypersensitivity.
Development History and FDA Approval Process for Afstyla
|May 26, 2016||FDA Approves Afstyla (Antihemophilic Factor (Recombinant), Single Chain) for Hemophilia A|
|Jul 28, 2015||FDA Accepts for Review CSL Behring’s BLA for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.